Voyager Therapeutics Inc (NASDAQ: VYGR) on Tuesday, soared 6.55% from the previous trading day, before settling in for the closing price of $3.36. Within the past 52 weeks, VYGR’s price has moved between $2.64 and $8.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 1.48% over the last five years. The company achieved an average annual earnings per share of -87.09%. With a float of $45.31 million, this company’s outstanding shares have now reached $55.43 million.
The firm has a total of 172 workers. Let’s measure their productivity.
Voyager Therapeutics Inc (VYGR) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Voyager Therapeutics Inc is 18.31%, while institutional ownership is 60.01%. The most recent insider transaction that took place on Aug 18 ’25, was worth 70,870. In this transaction Chief Medical Officer of this company sold 19,000 shares at a rate of $3.73, taking the stock ownership to the 138,914 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Officer proposed sale 19,000 for $3.72, making the entire transaction worth $70,680.
Voyager Therapeutics Inc (VYGR) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.16 earnings per share (EPS) for the period topping the consensus outlook (set at -0.41) by 0.25. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -87.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.71% during the next five years compared to 1.48% growth over the previous five years of trading.
Voyager Therapeutics Inc (NASDAQ: VYGR) Trading Performance Indicators
Voyager Therapeutics Inc (VYGR) is currently performing well based on its current performance indicators. A quick ratio of 5.43 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.85, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -1.49 in one year’s time.
Technical Analysis of Voyager Therapeutics Inc (VYGR)
Analysing the last 5-days average volume posted by the [Voyager Therapeutics Inc, VYGR], we can find that recorded value of 0.41 million was lower than the volume posted last year of 0.53 million. As of the previous 9 days, the stock’s Stochastic %D was 36.12%.
During the past 100 days, Voyager Therapeutics Inc’s (VYGR) raw stochastic average was set at 74.50%, which indicates a significant increase from 48.80% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.21 in the past 14 days, which was lower than the 0.22 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.29, while its 200-day Moving Average is $4.16. Now, the first resistance to watch is $3.71. This is followed by the second major resistance level at $3.85. The third major resistance level sits at $4.04. If the price goes on to break the first support level at $3.39, it is likely to go to the next support level at $3.19. Now, if the price goes above the second support level, the third support stands at $3.06.
Voyager Therapeutics Inc (NASDAQ: VYGR) Key Stats
Market capitalization of the company is 198.58 million based on 55,469K outstanding shares. Right now, sales total 80,000 K and income totals -65,000 K. The company made 5,200 K in profit during its latest quarter, and -33,380 K in sales during its previous quarter.
